Endothelial cell adhesion molecule (ECAM) (ECAM)

Endothelial cell adhesion molecules (ECAMs) are a diverse group of cell surface glycoproteins, including Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), and E-selectin, that mediate the recruitment of leukocytes from the blood into tissues (PMID: 11544344). These molecules are typically expressed at low levels but are rapidly upregulated by pro-inflammatory cytokines such as TNF-alpha and IL-1 beta during the inflammatory response (PMID: 15123770). Their primary biological function is to facilitate the multi-step process of leukocyte tethering, rolling, firm adhesion, and eventual transendothelial migration (diapedesis) (StatPearls: Inflammation). In chronic disease states, persistent expression of these molecules contributes to the pathogenesis of atherosclerosis, rheumatoid arthritis, and the metastatic spread of cancer cells (PMID: 10864928). Therapeutic targeting of these molecules or their expression levels is a key strategy in managing inflammatory and autoimmune disorders. For instance, monoclonal antibodies like natalizumab and vedolizumab work by blocking the interaction between leukocyte integrins and their endothelial ligands (e.g., VCAM-1 or MAdCAM-1), thereby preventing tissue-specific inflammation (PubMed: 24645854). Additionally, small molecules and antisense oligonucleotides like alicaforsen have been investigated to directly inhibit the expression of ICAM-1 (PMID: 15651903). While effective, inhibiting these pathways carries risks such as impaired immune surveillance and increased susceptibility to opportunistic infections like progressive multifocal leukoencephalopathy (PML) (FDA: Tysabri Safety). Soluble forms of these molecules (sICAM-1, sVCAM-1) are frequently used as clinical biomarkers to assess endothelial activation and the efficacy of anti-inflammatory therapies (PMID: 10864928).

Other names

Endothelial adhesion moleculeVascular adhesion moleculeCell adhesion moleculeCAM

Inhibition of leukocyte-endothelial interactions by blocking the binding of leukocyte integrins to endothelial ligands or by downregulating the expression of adhesion molecules on the endothelial surface.